{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:07:19Z","timestamp":1780758439005,"version":"3.54.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40272-021-00464-0","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T02:02:36Z","timestamp":1629079356000},"page":"425-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Management of IgA Vasculitis with Nephritis"],"prefix":"10.1007","volume":"23","author":[{"given":"Jean-Daniel","family":"Delbet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Herbez Rea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Mouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Ulinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/ard.2009.116657","volume":"69","author":"S Ozen","year":"2010","unstructured":"Ozen S, Pistorio A, Iusan SM, et al. EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798\u2013806. https:\/\/doi.org\/10.1136\/ard.2009.116657.","journal-title":"Ann Rheum Dis"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(02)11279-7","volume":"360","author":"JMM Gardner-Medwin","year":"2002","unstructured":"Gardner-Medwin JMM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch\u2013Sch\u00f6nlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet Lond Engl. 2002;360:1197\u2013202. https:\/\/doi.org\/10.1016\/S0140-6736(02)11279-7.","journal-title":"Lancet Lond Engl"},{"key":"464_CR3","doi-asserted-by":"crossref","unstructured":"Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch\u2013Sch\u00f6nlein Purpura (HSP). In: The Cochrane Collaboration (ed.) Cochrane Database of Systematic Reviews. Chichester: Wiley; 2009.","DOI":"10.1002\/14651858.CD005128.pub2"},{"key":"464_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/BF00442205","volume":"147","author":"M Stewart","year":"1988","unstructured":"Stewart M, Savage JM, Bell B, McCord B. Long term renal prognosis of Henoch\u2013Sch\u00f6nlein purpura in an unselected childhood population. Eur J Pediatr. 1988;147:113\u20135.","journal-title":"Eur J Pediatr"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/0140-6736(92)91341-5","volume":"339","author":"AR Goldstein","year":"1992","unstructured":"Goldstein AR, White RH, Akuse R, Chantler C. Long-term follow-up of childhood Henoch\u2013Sch\u00f6nlein nephritis. Lancet Lond Engl. 1992;339:280\u20132.","journal-title":"Lancet Lond Engl"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jpeds.2006.03.024","volume":"149","author":"J Ronkainen","year":"2006","unstructured":"Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch\u2013Sch\u00f6nlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2006;149:241\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2006.03.024.","journal-title":"J Pediatr"},{"issue":"3","key":"464_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s004670050446","volume":"12","author":"P Niaudet","year":"1998","unstructured":"Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Sch\u00f6nlein\u2013Henoch purpura nephritis. Pediatr Nephrol. 1998;12(3):238\u201343. https:\/\/doi.org\/10.1007\/s004670050446.","journal-title":"Pediatr Nephrol"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1007\/s00467-008-1066-9","volume":"24","author":"M Zaffanello","year":"2009","unstructured":"Zaffanello M, Fanos V. Treatment-based literature of Henoch-Sch\u00f6nlein purpura nephritis in childhood. Pediatr Nephrol Berl Ger. 2009;24:1901\u201311. https:\/\/doi.org\/10.1007\/s00467-008-1066-9.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR9","doi-asserted-by":"publisher","unstructured":"Chapter 11: Henoch\u2013Sch\u00f6nlein purpura nephritis. Kidney Int Suppl. 2012;2:218\u201320. https:\/\/doi.org\/10.1038\/kisup.2012.24.","DOI":"10.1038\/kisup.2012.24"},{"key":"464_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00467-009-1230-x","volume":"25","author":"KK Lau","year":"2010","unstructured":"Lau KK, Suzuki H, Novak J, Wyatt RJ. Pathogenesis of Henoch-Sch\u00f6nlein purpura nephritis. Pediatr Nephrol Berl Ger. 2010;25:19\u201326. https:\/\/doi.org\/10.1007\/s00467-009-1230-x.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/ki.2011.16","volume":"80","author":"K Kiryluk","year":"2011","unstructured":"Kiryluk K, Moldoveanu Z, Sanders JT, et al. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Sch\u00f6nlein purpura nephritis. Kidney Int. 2011;80:79\u201387. https:\/\/doi.org\/10.1038\/ki.2011.16.","journal-title":"Kidney Int"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1084\/jem.194.4.417","volume":"194","author":"IC Moura","year":"2001","unstructured":"Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med. 2001;194:417\u201325. https:\/\/doi.org\/10.1084\/jem.194.4.417.","journal-title":"J Exp Med"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.rinim.2012.08.002","volume":"2","author":"T Yanagihara","year":"2012","unstructured":"Yanagihara T, Brown R, Hall S, et al. In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol. 2012;2:166\u201372. https:\/\/doi.org\/10.1016\/j.rinim.2012.08.002.","journal-title":"Results Immunol"},{"key":"464_CR14","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.4049\/jimmunol.1300261","volume":"192","author":"E Aleyd","year":"2014","unstructured":"Aleyd E, van Hout MWM, Ganzevles SH, et al. IgA enhances NETosis and release of neutrophil extracellular traps by polymorphonuclear cells via Fc\u03b1 receptor I. J Immunol Baltim Md. 2014;192:2374\u201383. https:\/\/doi.org\/10.4049\/jimmunol.1300261.","journal-title":"J Immunol Baltim Md"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1046\/j.1365-2249.2002.01964.x","volume":"130","author":"Y-H Yang","year":"2002","unstructured":"Yang Y-H, Wang SJ, Chuang Y-H, et al. The level of IgA antibodies to human umbilical vein endothelial cells can be enhanced by TNF-alpha treatment in children with Henoch\u2013Sch\u00f6nlein purpura. Clin Exp Immunol. 2002;130:352\u20137. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01964.x.","journal-title":"Clin Exp Immunol"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1136\/ard.2005.035295","volume":"65","author":"C Belizna","year":"2006","unstructured":"Belizna C, Duijvestijn A, Hamidou M, Tervaert JWC. Antiendothelial cell antibodies in vasculitis and connective tissue disease. Ann Rheum Dis. 2006;65:1545\u201350. https:\/\/doi.org\/10.1136\/ard.2005.035295.","journal-title":"Ann Rheum Dis"},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1681\/ASN.2005090923","volume":"17","author":"A Roos","year":"2006","unstructured":"Roos A, Rastaldi MP, Calvaresi N, et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006;17:1724\u201334. https:\/\/doi.org\/10.1681\/ASN.2005090923.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR18","doi-asserted-by":"publisher","first-page":"e40495","DOI":"10.1371\/journal.pone.0040495","volume":"7","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Koo HM, Lim BJ, et al. Decreased circulating C3 levels and mesangial C3 deposition predict renal outcome in patients with IgA nephropathy. PLoS ONE. 2012;7:e40495. https:\/\/doi.org\/10.1371\/journal.pone.0040495.","journal-title":"PLoS ONE"},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1681\/ASN.2015010012","volume":"27","author":"Y-L Zhai","year":"2016","unstructured":"Zhai Y-L, Meng S-J, Zhu L, et al. Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J Am Soc Nephrol. 2016;27:2894\u2013905. https:\/\/doi.org\/10.1681\/ASN.2015010012.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch\u2013Sch\u00f6nlein purpura). Autoimmun Rev. 2017;16:1246\u201353. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.009.","journal-title":"Autoimmun Rev"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmj.2.6078.11","volume":"2","author":"R Counahan","year":"1977","unstructured":"Counahan R, Winterborn MH, White RH, et al. Prognosis of Henoch\u2013Sch\u00f6nlein nephritis in children. Br Med J. 1977;2:11\u20134. https:\/\/doi.org\/10.1136\/bmj.2.6078.11.","journal-title":"Br Med J"},{"key":"464_CR22","first-page":"241","volume":"41","author":"SR Meadow","year":"1972","unstructured":"Meadow SR, Glasgow EF, White RH, et al. Sch\u00f6nlein-Henoch nephritis. Q J Med. 1972;41:241\u201358.","journal-title":"Q J Med"},{"key":"464_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/S0140-6736(02)09835-5","volume":"360","author":"J Ronkainen","year":"2002","unstructured":"Ronkainen J, Nuutinen M, Koskimies O. The adult kidney 24 years after childhood Henoch\u2013Sch\u00f6nlein purpura: a retrospective cohort study. Lancet Lond Engl. 2002;360:666\u201370. https:\/\/doi.org\/10.1016\/S0140-6736(02)09835-5.","journal-title":"Lancet Lond Engl"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00467-010-1444-y","volume":"25","author":"S Edstr\u00f6m Halling","year":"2010","unstructured":"Edstr\u00f6m Halling S, S\u00f6derberg MP, Berg UB. Predictors of outcome in Henoch\u2013Sch\u00f6nlein nephritis. Pediatr Nephrol Berl Ger. 2010;25:1101\u20138. https:\/\/doi.org\/10.1007\/s00467-010-1444-y.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00467-011-1827-8","volume":"26","author":"H Wakaki","year":"2011","unstructured":"Wakaki H, Ishikura K, Hataya H, et al. Henoch\u2013Sch\u00f6nlein purpura nephritis with nephrotic state in children: predictors of poor outcomes. Pediatr Nephrol Berl Ger. 2011;26:921\u20135. https:\/\/doi.org\/10.1007\/s00467-011-1827-8.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.asn.0000013883.99976.22","volume":"13","author":"E Pillebout","year":"2002","unstructured":"Pillebout E, Thervet E, Hill G, et al. Henoch\u2013Sch\u00f6nlein Purpura in adults: outcome and prognostic factors. J Am Soc Nephrol JASN. 2002;13:1271\u20138. https:\/\/doi.org\/10.1097\/01.asn.0000013883.99976.22.","journal-title":"J Am Soc Nephrol JASN"},{"key":"464_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00467-019-04363-y","volume":"35","author":"J-D Delbet","year":"2020","unstructured":"Delbet J-D, Geslain G, Auger M, et al. Histological prognostic factors in children with Henoch\u2013Sch\u00f6nlein purpura nephritis. Pediatr Nephrol Berl Ger. 2020;35:313\u201320. https:\/\/doi.org\/10.1007\/s00467-019-04363-y.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"e0166830","DOI":"10.1371\/journal.pone.0166830","volume":"11","author":"MJ Kim","year":"2016","unstructured":"Kim MJ, Schaub S, Molyneux K, et al. Effect of immunosuppressive drugs on the changes of serum galactose-deficient IgA1 in patients with IgA nephropathy. PLoS ONE. 2016;11:e0166830. https:\/\/doi.org\/10.1371\/journal.pone.0166830.","journal-title":"PLoS ONE"},{"key":"464_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00467-017-3604-9","volume":"32","author":"JD Delbet","year":"2017","unstructured":"Delbet JD, Hogan J, Aoun B, et al. Clinical outcomes in children with Henoch\u2013Sch\u00f6nlein purpura nephritis without crescents. Pediatr Nephrol Berl Ger. 2017;32:1193\u20139. https:\/\/doi.org\/10.1007\/s00467-017-3604-9.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/s0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet Lond Engl. 1999;353:883\u20137. https:\/\/doi.org\/10.1016\/s0140-6736(98)03563-6.","journal-title":"Lancet Lond Engl"},{"key":"464_CR31","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24:3694\u2013701. https:\/\/doi.org\/10.1093\/ndt\/gfp356.","journal-title":"Nephrol Dial Transpl"},{"key":"464_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/j.ajkd.2008.07.029","volume":"53","author":"J Lv","year":"2009","unstructured":"Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26\u201332. https:\/\/doi.org\/10.1053\/j.ajkd.2008.07.029.","journal-title":"Am J Kidney Dis"},{"key":"464_CR33","doi-asserted-by":"publisher","unstructured":"Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3:CD003965. https:\/\/doi.org\/10.1002\/14651858.CD003965.pub3.","DOI":"10.1002\/14651858.CD003965.pub3"},{"key":"464_CR34","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98:1044\u201352. https:\/\/doi.org\/10.1016\/j.kint.2020.04.046.","journal-title":"Kidney Int"},{"key":"464_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/archdischild-2013-303642","volume":"98","author":"J Dudley","year":"2013","unstructured":"Dudley J, Smith G, Llewelyn-Edwards A, et al. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schonlein Purpura (HSP). Arch Dis Child. 2013;98:756\u201363. https:\/\/doi.org\/10.1136\/archdischild-2013-303642.","journal-title":"Arch Dis Child"},{"key":"464_CR36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1542\/peds.111.4.785","volume":"111","author":"Y Kawasaki","year":"2003","unstructured":"Kawasaki Y, Suzuki J, Nozawa R, et al. Efficacy of methylprednisolone and urokinase pulse therapy for severe Henoch\u2013Sch\u00f6nlein nephritis. Pediatrics. 2003;111:785\u20139. https:\/\/doi.org\/10.1542\/peds.111.4.785.","journal-title":"Pediatrics"},{"key":"464_CR37","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/ndt\/gfn394","volume":"23","author":"R Katafuchi","year":"2008","unstructured":"Katafuchi R, Ninomiya T, Mizumasa T, et al. The improvement of renal survival with steroid pulse therapy in IgA nephropathy. Nephrol Dial Transpl. 2008;23:3915\u201320. https:\/\/doi.org\/10.1093\/ndt\/gfn394.","journal-title":"Nephrol Dial Transpl"},{"key":"464_CR38","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/apa.12723","volume":"104","author":"E Tudorache","year":"2015","unstructured":"Tudorache E, Azema C, Hogan J, et al. Even mild cases of paediatric Henoch-Sch\u00f6nlein purpura nephritis show significant long-term proteinuria. Acta Paediatr. 2015;104:843\u20138. https:\/\/doi.org\/10.1111\/apa.12723.","journal-title":"Acta Paediatr"},{"key":"464_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00467-010-1741-5","volume":"26","author":"T Ninchoji","year":"2011","unstructured":"Ninchoji T, Kaito H, Nozu K, et al. Treatment strategies for Henoch-Sch\u00f6nlein purpura nephritis by histological and clinical severity. Pediatr Nephrol Berl Ger. 2011;26:563\u20139. https:\/\/doi.org\/10.1007\/s00467-010-1741-5.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR40","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, et al. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol JASN. 2003;14:1578\u201383.","journal-title":"J Am Soc Nephrol JASN"},{"key":"464_CR41","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880\u20138. https:\/\/doi.org\/10.1681\/ASN.2006040347.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR42","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK-T Li","year":"2006","unstructured":"Li PK-T, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751\u201360. https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.017.","journal-title":"Am J Kidney Dis"},{"key":"464_CR43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00467-003-1245-7","volume":"18","author":"J Ronkainen","year":"2003","unstructured":"Ronkainen J, Autio-Harmainen H, Nuutinen M. Cyclosporin A for the treatment of severe Henoch\u2013Sch\u00f6nlein glomerulonephritis. Pediatr Nephrol Berl Ger. 2003;18:1138\u201342. https:\/\/doi.org\/10.1007\/s00467-003-1245-7.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/03009740510026544","volume":"34","author":"JI Shin","year":"2005","unstructured":"Shin JI, Park JM, Shin YH, et al. Henoch-Sch\u00f6nlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment. Scand J Rheumatol. 2005;34:392\u20135. https:\/\/doi.org\/10.1080\/03009740510026544.","journal-title":"Scand J Rheumatol"},{"key":"464_CR45","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00467-011-1919-5","volume":"26","author":"O Jauhola","year":"2011","unstructured":"Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch-Sch\u00f6nlein nephritis: a randomized trial. Pediatr Nephrol Berl Ger. 2011;26:2159\u201366. https:\/\/doi.org\/10.1007\/s00467-011-1919-5.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR46","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5414\/cn106553","volume":"75","author":"P Kalliakmani","year":"2011","unstructured":"Kalliakmani P, Benou E, Goumenos DS. Cyclosporin A in adult patients with Henoch-Sch\u00f6nlein purpura nephritis and nephrotic syndrome; 5 case reports. Clin Nephrol. 2011;75:380\u20133. https:\/\/doi.org\/10.5414\/cn106553.","journal-title":"Clin Nephrol"},{"key":"464_CR47","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1111\/1346-8138.13614","volume":"44","author":"S Ichiyama","year":"2017","unstructured":"Ichiyama S, Matayoshi T, Kaneko T, et al. Successful multitarget therapy using prednisolone, mizoribine and tacrolimus for Henoch\u2013Sch\u00f6nlein purpura nephritis in children. J Dermatol. 2017;44:e56\u20137. https:\/\/doi.org\/10.1111\/1346-8138.13614.","journal-title":"J Dermatol"},{"key":"464_CR48","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/archdischild-2017-313788","volume":"103","author":"D-F Zhang","year":"2018","unstructured":"Zhang D-F, Hao G-X, Li C-Z, et al. Off-label use of tacrolimus in children with Henoch-Sch\u00f6nlein purpura nephritis: a pilot study. Arch Dis Child. 2018;103:772\u20135. https:\/\/doi.org\/10.1136\/archdischild-2017-313788.","journal-title":"Arch Dis Child"},{"key":"464_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","volume":"18","author":"Y-H Song","year":"2017","unstructured":"Song Y-H, Cai G-Y, Xiao Y-F, et al. Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis. BMC Nephrol. 2017;18:61. https:\/\/doi.org\/10.1186\/s12882-017-0467-z.","journal-title":"BMC Nephrol"},{"key":"464_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00467-003-1315-x","volume":"19","author":"P Tarshish","year":"2004","unstructured":"Tarshish P, Bernstein J, Edelmann CM. Henoch-Sch\u00f6nlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol Berl Ger. 2004;19:51\u20136. https:\/\/doi.org\/10.1007\/s00467-003-1315-x.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ki.2010.150","volume":"78","author":"E Pillebout","year":"2010","unstructured":"Pillebout E, Alberti C, Guillevin L, et al. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Sch\u00f6nlein Purpura. Kidney Int. 2010;78:495\u2013502. https:\/\/doi.org\/10.1038\/ki.2010.150.","journal-title":"Kidney Int"},{"key":"464_CR52","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/art.40178","volume":"69","author":"A Audemard-Verger","year":"2017","unstructured":"Audemard-Verger A, Terrier B, Dechartres A, et al. Characteristics and management of IgA Vasculitis (Henoch-Sch\u00f6nlein) in adults: data from 260 patients included in a French Multicenter Retrospective Survey. Arthritis Rheumatol Hoboken NJ. 2017;69:1862\u201370. https:\/\/doi.org\/10.1002\/art.40178.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"464_CR53","first-page":"9","volume":"49","author":"J Bergstein","year":"1998","unstructured":"Bergstein J, Leiser J, Andreoli SP. Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol. 1998;49:9\u201314.","journal-title":"Clin Nephrol"},{"key":"464_CR54","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1067\/mpd.2000.103448","volume":"136","author":"BJ Foster","year":"2000","unstructured":"Foster BJ, Bernard C, Drummond KN, Sharma AK. Effective therapy for severe Henoch-Schonlein purpura nephritis with prednisone and azathioprine: a clinical and histopathologic study. J Pediatr. 2000;136:370\u20135. https:\/\/doi.org\/10.1067\/mpd.2000.103448.","journal-title":"J Pediatr"},{"key":"464_CR55","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00296-002-0208-9","volume":"22","author":"SS Devidayal","year":"2002","unstructured":"Devidayal SS, Kumar L, et al. Severe Henoch-Sch\u00f6nlein nephritis: resolution with azathioprine and steroids. Rheumatol Int. 2002;22:133\u20137. https:\/\/doi.org\/10.1007\/s00296-002-0208-9.","journal-title":"Rheumatol Int"},{"key":"464_CR56","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.02300215","volume":"11","author":"C Sarcina","year":"2016","unstructured":"Sarcina C, Tinelli C, Ferrario F, et al. Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy. Clin J Am Soc Nephrol. 2016;11:973\u201381. https:\/\/doi.org\/10.2215\/CJN.02300215.","journal-title":"Clin J Am Soc Nephrol"},{"key":"464_CR57","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00467-011-2057-9","volume":"27","author":"Y Du","year":"2012","unstructured":"Du Y, Hou L, Zhao C, et al. Treatment of children with Henoch-Sch\u00f6nlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol Berl Ger. 2012;27:765\u201371. https:\/\/doi.org\/10.1007\/s00467-011-2057-9.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.4103\/1319-2442.135182","volume":"25","author":"AA Nikibakhsh","year":"2014","unstructured":"Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, et al. Treatment of severe henoch-schonlein purpura nephritis with mycophenolate mofetil. Saudi J Kidney Dis Transpl. 2014;25:858\u201363. https:\/\/doi.org\/10.4103\/1319-2442.135182.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"464_CR59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000341914","volume":"36","author":"P Ren","year":"2012","unstructured":"Ren P, Han F, Chen L, et al. The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch\u2013Sch\u00f6nlein purpura nephritis. Am J Nephrol. 2012;36:271\u20137. https:\/\/doi.org\/10.1159\/000341914.","journal-title":"Am J Nephrol"},{"key":"464_CR60","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1631\/jzus.B1400335","volume":"16","author":"F Han","year":"2015","unstructured":"Han F, Chen L, Ren P, et al. Mycophenolate mofetil plus prednisone for inducing remission of Henoch-Sch\u00f6nlein purpura nephritis: a retrospective study. J Zhejiang Univ Sci B. 2015;16:772\u20139. https:\/\/doi.org\/10.1631\/jzus.B1400335.","journal-title":"J Zhejiang Univ Sci B"},{"key":"464_CR61","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-017-0647-x","volume":"18","author":"B Du","year":"2017","unstructured":"Du B, Jia Y, Zhou W, et al. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis. BMC Nephrol. 2017;18:245. https:\/\/doi.org\/10.1186\/s12882-017-0647-x.","journal-title":"BMC Nephrol"},{"key":"464_CR62","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/ndt\/gft318","volume":"29","author":"F Alberici","year":"2014","unstructured":"Alberici F, Jayne DRW. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Nephrol Dial Transpl. 2014;29:1151\u20139. https:\/\/doi.org\/10.1093\/ndt\/gft318.","journal-title":"Nephrol Dial Transpl"},{"key":"464_CR63","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/ndt\/gfr137","volume":"26","author":"E Pillebout","year":"2011","unstructured":"Pillebout E, Rocha F, Fardet L, et al. Successful outcome using rituximab as the only immunomodulation in Henoch\u2013Schonlein purpura: case report. Nephrol Dial Transpl. 2011;26:2044\u20136. https:\/\/doi.org\/10.1093\/ndt\/gfr137.","journal-title":"Nephrol Dial Transpl"},{"key":"464_CR64","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpeds.2008.12.049","volume":"155","author":"KJ Donnithorne","year":"2009","unstructured":"Donnithorne KJ, Atkinson TP, Hinze CH, et al. Rituximab therapy for severe refractory chronic Henoch\u2013Sch\u00f6nlein purpura. J Pediatr. 2009;155:136\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2008.12.049.","journal-title":"J Pediatr"},{"key":"464_CR65","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s12026-016-8827-5","volume":"65","author":"R Fenoglio","year":"2017","unstructured":"Fenoglio R, Naretto C, Basolo B, et al. Rituximab therapy for IgA-vasculitis with nephritis: a case series and review of the literature. Immunol Res. 2017;65:186\u201392. https:\/\/doi.org\/10.1007\/s12026-016-8827-5.","journal-title":"Immunol Res"},{"key":"464_CR66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/art.40339","volume":"70","author":"F Maritati","year":"2018","unstructured":"Maritati F, Fenoglio R, Pillebout E, et al. Brief Report: Rituximab for the Treatment of Adult-Onset IgA Vasculitis (Henoch-Sch\u00f6nlein). Arthritis Rheumatol Hoboken NJ. 2018;70:109\u201314. https:\/\/doi.org\/10.1002\/art.40339.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"464_CR67","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of Rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306\u201313. https:\/\/doi.org\/10.1681\/ASN.2016060640.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR68","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/adc.75.3.186","volume":"75","author":"A Gianviti","year":"1996","unstructured":"Gianviti A, Trompeter RS, Barratt TM, et al. Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child. 1996;75:186\u201390.","journal-title":"Arch Dis Child"},{"key":"464_CR69","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0272-6386(99)70178-2","volume":"33","author":"M Hattori","year":"1999","unstructured":"Hattori M, Ito K, Konomoto T, et al. Plasmapheresis as the sole therapy for rapidly progressive Henoch\u2013Sch\u00f6nlein purpura nephritis in children. Am J Kidney Dis. 1999;33:427\u201333.","journal-title":"Am J Kidney Dis"},{"key":"464_CR70","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s004670050707","volume":"13","author":"K Sch\u00e4rer","year":"1999","unstructured":"Sch\u00e4rer K, Krmar R, Querfeld U, et al. Clinical outcome of Sch\u00f6nlein\u2013Henoch purpura nephritis in children. Pediatr Nephrol Berl Ger. 1999;13:816\u201323. https:\/\/doi.org\/10.1007\/s004670050707.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR71","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00467-007-0498-y","volume":"22","author":"M Shenoy","year":"2007","unstructured":"Shenoy M, Ognjanovic MV, Coulthard MG. Treating severe Henoch-Sch\u00f6nlein and IgA nephritis with plasmapheresis alone. Pediatr Nephrol Berl Ger. 2007;22:1167\u201371. https:\/\/doi.org\/10.1007\/s00467-007-0498-y.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR72","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1053\/j.ajkd.2011.12.015","volume":"59","author":"J-F Augusto","year":"2012","unstructured":"Augusto J-F, Sayegh J, Delapierre L, et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Sch\u00f6nlein purpura in adults: a case series. Am J Kidney Dis. 2012;59:663\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2011.12.015.","journal-title":"Am J Kidney Dis"},{"key":"464_CR73","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3345\/kjp.2019.00514","volume":"63","author":"KH Lee","year":"2020","unstructured":"Lee KH, Hong SH, Jun J, et al. Treatment of refractory IgA vasculitis with dapsone: a systematic review. Clin Exp Pediatr. 2020;63:158\u201363. https:\/\/doi.org\/10.3345\/kjp.2019.00514.","journal-title":"Clin Exp Pediatr"},{"key":"464_CR74","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/adc.2004.061598","volume":"90","author":"H Iqbal","year":"2005","unstructured":"Iqbal H, Evans A. Dapsone therapy for Henoch\u2013Sch\u00f6nlein purpura: a case series. Arch Dis Child. 2005;90:985\u20136. https:\/\/doi.org\/10.1136\/adc.2004.061598.","journal-title":"Arch Dis Child"},{"key":"464_CR75","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/s0190-9622(87)70100-5","volume":"16","author":"MF Fredenberg","year":"1987","unstructured":"Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol. 1987;16:772\u20138. https:\/\/doi.org\/10.1016\/s0190-9622(87)70100-5.","journal-title":"J Am Acad Dermatol"},{"key":"464_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","volume":"10","author":"DV Rizk","year":"2019","unstructured":"Rizk DV, Maillard N, Julian BA, et al. The emerging role of complement proteins as a target for therapy of IgA nephropathy. Front Immunol. 2019;10:504. https:\/\/doi.org\/10.3389\/fimmu.2019.00504.","journal-title":"Front Immunol"},{"key":"464_CR77","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ekir.2020.08.003","volume":"5","author":"RA Lafayette","year":"2020","unstructured":"Lafayette RA, Rovin BH, Reich HN, et al. Safety, tolerability and efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the treatment of IgA Nephropathy. Kidney Int Rep. 2020;5:2032\u201341. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.003.","journal-title":"Kidney Int Rep"},{"key":"464_CR78","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1053\/j.ajkd.2006.02.178","volume":"47","author":"R Coppo","year":"2006","unstructured":"Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Sch\u00f6nlein nephritis in children and adults. Am J Kidney Dis. 2006;47:993\u20131003. https:\/\/doi.org\/10.1053\/j.ajkd.2006.02.178.","journal-title":"Am J Kidney Dis"},{"key":"464_CR79","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00467-017-3794-1","volume":"33","author":"I Hennies","year":"2018","unstructured":"Hennies I, Gimpel C, Gellermann J, et al. Presentation of pediatric Henoch-Sch\u00f6nlein purpura nephritis changes with age and renal histology depends on biopsy timing. Pediatr Nephrol Berl Ger. 2018;33:277\u201386. https:\/\/doi.org\/10.1007\/s00467-017-3794-1.","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"464_CR80","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/rheumatology\/keaa057","volume":"59","author":"N de Graeff","year":"2020","unstructured":"de Graeff N, Groot N, Brogan P, et al. European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides\u2014the SHARE initiative. Rheumatol Oxf Engl. 2020;59:919. https:\/\/doi.org\/10.1093\/rheumatology\/keaa057.","journal-title":"Rheumatol Oxf Engl"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-021-00464-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-021-00464-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T15:11:30Z","timestamp":1630768290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-021-00464-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1007\/s40272-021-00464-0","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"25 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jean-Daniel Delbet, Cyrielle Parmentier, Claire Herbez Rea, Antoine Mouche, and Tim Ulinski have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"J-DD wrote the first version of the manuscript, examined the appropriate literature, coordinated the different steps of the submission process, and responded to the reviewers\u2019 remarks. CP, AM, and CH participated in the literature search and discussion of the manuscript. TU revised and discussed the manuscript and validated the final version and the responses to the reviewers\u2019 remarks.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}